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Abstract: Women are advised not to attempt pregnancy while on hydroxyurea (HU) due to 
the teratogenic effects of this agent, based on results obtained from animal studies. Several 
case reports suggest that HU may have minimal or no teratogenic effects on the developing 
human fetus. Fourteen cases of HU therapy in pregnant patients diagnosed with acute or 
chronic myelogenous leukemia, primary thrombocythemia, or sickle cell disease (SCD) 
have been reported. Three pregnancies were terminated by elective abortion; 1 woman 
developed eclampsia and delivered a phenotypically normal stillborn infant. All other 
patients delivered live, healthy infants without congenital anomalies. We contend that case 
studies such as these have too few patients and cannot effectively address the adverse 
effect of HU on preimplantation embryo or fetuses. The objective of this study was to 
assess the risks associated with a clinically relevant dose of HU used for the treatment of 
SCD, on ovulation rate and embryo development, using adult C57BL/6J female mice as a 
model. In Experiment 1, adult female mice were randomly assigned to a treatment or a 
control group (N = 20/group). Treatment consisted of oral HU (30 mg/kg) for 28 days; 
while control mice received saline (HU vehicle). Five days to the cessation of HU dosing, 
all mice were subjected to folliculogenesis induction with pregnant mare serum 
gonadotropin (PMSG). Five mice/group were anesthetized at 48 hours post PMSG to 
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facilitate blood collection via cardiac puncture for estradiol-17 (E2) measurement by RIA. 
Ovulation was induced in the remaining mice at 48 hours post PMSG with human 
chorionic gonadotropin (hCG) and immediately caged with adult males for mating. Five 
plugged female mice/group were sacrificed for the determination of ovulation rate. The 
remaining mated mice were sacrificed about 26 hours post hCG, ovaries excised and 
weighed and embryos harvested and cultured in Whitten’s medium (WM) supplemented 
with CZBt. In Experiments 2 and 3, (N = 10/Experiment) folliculogenesis and ovulation 
were induced in untreated mice followed by mating. Recovered embryos were either 
exposed continuously (Experiment 2) or intermittently (Experiment 3) to bioavailable HU 
(18 g HU/mL of WM + CZBt) or WM + CZBt only (control). Treated mice sustained 
decreased ovarian wt, ovulation rate and circulating E2 compared with controls (P < 0.05). 
Fewer embryos retrieved from HU-treated mice developed to blastocyst stage (32%) 
compared with those from controls (60%; P < 0.05). Furthermore, continuous or 
intermittent in vitro exposures of embryos to HU also resulted in reduced development to 
blastocyst stage (continuous HU, 9 vs. control, 63%; P < 0.05; intermittent HU, 20 vs. 
control, 62%; P < 0.05) with embryos exposed continuously to HU in vitro fairing worse. 
Even though HU is well tolerated, our data suggest that it compromises folliculogenesis 
and the ability of generated embryos to develop. Therefore, designed studies with larger 
numbers of patients receiving HU during pregnancy, with longer follow-up of exposed 
children and more careful assessment of embryo/fetotoxic effects, are required before this 
agent can be promoted as safe in pregnancy.  
 
Keywords:  ovarian weight; estradiol-17 ovulation rate; 2-cell embryo; blastocyst; 
hydroxyurea 
 
 
 
1. Introduction  
 
Hydroxyurea (HU) is a low molecular weight nonalkylating myelosuppressive agent that impairs 
DNA synthesis through the inhibition of ribonucleotide reductase [1]. This drug is often used to 
supplement phlebotomy for patients with polycythemia vera (PV; [2]) and to reduce significantly the 
incidence of recurrent thrombosis in patients with essential thrombocythemia who are at high risk [3]. 
Even though the therapeutic use of HU may be declining in patients with chronic myeloid   
leukemia [4], its use for the treatment of patients with sickle cell disease (SCD; [5]) is gaining 
acceptance. In the latter patients, HU alleviates the classical symptoms of the SCD not by its anti-
mitotic effect but by provoking increased production of fetal hemoglobin which has a higher oxygen 
carrying capacity than sickle cell hemoglobin. Currently, HU is used investigatively for the treatment 
of human immunodeficiency virus (HIV) infection [6,7]. In the latter treatment, HU does not have a 
direct anti-virus activity; rather, it inhibits the cellular enzyme ribonucleotide reductase and as a 
consequence, reduces deoxynucleotide triphosphates (dNTPs) that are necessary for DNA synthesis. Int. J. Environ. Res. Public Health 2010, 7          
 
 
2035
Depletion of the dNTP pool results in the arrest of the cell cycle at the G1 phase prior to DNA 
synthesis in HIV-infected cell. Incomplete reverse transcription of the viral genome also results from 
the depletion of dNTP pool [6]. 
Although HU is an approved drug for the treatment of the above mentioned diseases by the Food 
and Drug Administration, it poses a risk to the developmental competence of preimplantation embryos 
because of its anti-mitotic effect. Some teratogenic effects of HU have been observed in fetuses of 
treated pregnant rodents [8-10], hence the advice to women not to attempt pregnancy while on HU. 
However, several case reports suggest that HU may have minimal or no teratogenic effects on in vivo 
exposed developing human fetuses. Fourteen cases of hydroxyurea therapy in pregnant patients with 
acute or chronic myelogenous leukemia, primary thrombocythemia, or SCD have been reported [11]. 
Three pregnancies were terminated by elective abortion; 1 woman developed eclampsia and delivered 
a phenotypically normal stillborn infant. All other patients delivered live, healthy infants without 
congenital anomalies. The common denominator among the human studies is that they are case studies 
with limited number of subjects that are not amenable to statistical scrutiny. Besides, it is not known 
whether the patients took HU as prescribed or when pregnancy ensued. Because HU has 
antiproliferative properties due to its ability to inhibit DNA synthesis, we believe that it can hinder the 
active proliferation and growth of preimplantation embryos. The objective of this study was to assess 
the risks associated with a low clinically relevant dose of HU (30 mg/kg body weight/day; [12]) used 
for the treatment of SCD, on ovarian function and embryo development, using C57BL/6J strain of 
female mice as a model. 
 
2. Materials and Methods 
 
 Animals 
 
Adult male and female mice (strain C57BL/6J) 6–8 weeks of age were purchased from Jackson 
Laboratory (Bar Harbor, ME) and housed by sex (1 male or 4 females/cage) in stainless steel cages and 
allowed to acclimatize to the Animal Care Facilities for one week prior to initiation of studies. Mice 
were maintained in an environmentally controlled room with a 14-hour light and 10-hour dark cycle 
(lights on at 0600h), 22 
oC and a humidity range of 50–60%. All animals were allowed ad libitum 
access to commercial mouse chow and water.  
 
Experiment 1 
 
Female mice were randomly assigned to a treatment or a control group (N = 20/group). Treatment 
consisted of 30 mg HU/kg administered daily by oral gavage for 28 days. The dose of HU used in this 
study is similar to the daily dose of this drug routinely administered to sickle cell patients [12]. Control 
mice were administered with the vehicle to this drug (saline) as described above. Five days prior to the 
cessation of treatments, folliculogenesis was induced in each animal with an IP injection of 5 IU of 
pregnant mare serum gonadotropin (PMSG) between 1,300 and 1,400 h. Forty eight hours post PMSG, 
5 mice/group were anesthetized with isoflurane following which, laparotomy was performed to permit 
blood collection via the inferior vena cava puncture into serum separation tubes. Sera were separated Int. J. Environ. Res. Public Health 2010, 7          
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from blood cells by centrifugation at 1,500 × g for 10 minutes and stored frozen at −20C until assayed 
for estradiol-17β (E2).  
 
Ovulation Induction, Embryo Recovery and in vitro Culture 
 
Ovulation was induced at approximately 48 hours post PMSG in each of the remaining treated and 
control mice with an IP injection of 5 IU of human chorionic gonadotropin (hCG). Induced mice were 
subsequently placed with proven breeder males in a 1:1 ratio. The following morning, female mice 
were inspected for the presence of vaginal plugs as evidence of mating. Five mated females in the HU 
treatment or control group were sacrificed by CO2 asphyxiation immediately post detection of vaginal 
plugs (approximately 14–16 h post hCG), oviducts excised and flushed with Whitten’s medium   
(WM; [13]) containing 0.1% hyaluronidase and each flushing examined with a Nikon TMD inverted 
microscope at 200× magnification for the presence of cumulus masses. Each oviductal flushing was 
incubated at room temperature for approximately 10 minutes to permit the dispersion of cumulus cells 
from ovulated ova (one-cell embryos or non-fertilized oocytes). An ovum was considered fertilized if 
it contained 2 pronuclei in their cytoplasm and 2 polar bodies in the perivitelline space. Fertilized and 
non-fertilized ova were separated from the cumulus cells using pulled pipettes with the aid of an 
Olympus dissecting microscope. The total number of fertilized and non-fertilized oocytes per mouse 
was counted and considered as ovulation rate. The remaining mated mice were sacrificed at 26 to 28 
hours after detection of vaginal plugs, ovaries excised and dissected free of fat tissue and weighed. 
Oviducts were removed and flushed with WM [13] lacking bovine serum albumin (BSA). All 
procedures involving animal care, anesthesia, euthanasia, and tissue collection were approved by the 
Meharry Medical College Institutional Animal Use and Care Committee. The flushings were examined 
with a Nikon TMD inverted microscope at 200× magnification for the presence of 2-cell embryos. 
Figure 1 depicts a photomicrograph of a normal 2-cell mouse embryo. Normal 2-cell mouse embryos, 
each defined as an embryo with two blastomeres of equal size with two polar bodies in the perivitelline 
space and encompassed by an intact zona pellucida were pooled among mice within treatment and 
washed in several droplets of WM containing 1% BSA (Sigma Chemical Co., St. Louis, MO).  
Figure 1. Normal 2-cell embryo with two equal blastomeres (B), one of two polar bodies 
(PB) encompassed by an intact zona pellucida (ZP; magnification = 400X).  
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Embryos were cultured in WM supplemented with CZBt medium containing glucose and growth 
factors (glutamine and taurine) and 0.3% BSA (CM) at 37ºC in an atmosphere of 5% CO2 in air, for 
five days.  
 
Radioimmunoassay 
 
Serum samples were analyzed for E2, using radioimmunoassay previously validated in our 
laboratory [14]. The sensitivity of E2 assay was 2 pg/tube and the intra-and inter-assay coefficients of 
variation were 4.9 and 10.8%, respectively.  
 
Experiment 2 
 
In vitro Culture of Embryos in Bioavailable HU 
 
Folliculogenesis and ovulation were induced in adult female C57BL/6J strain of mice (N = 10) and 
mated to breeder males as described in experiment 1. Two-cell embryos were recovered at the time 
line indicated in experiment 1 and washed as detailed in experiment 1. Normal 2-cell embryos were 
selected based on the criteria listed in experiment 1 and subjected to continuous in vitro culture in CM 
in the presence or absence of bioavailable HU (steady serum concentration post HU treatment =   
18.0 g HU/mL for an hour before significant reduction close to nadir; [15]) at 37 ºC in an atmosphere 
of 5% CO2 in air, for five days. At the end of the culture period, the percentage of embryos at 
blastocyst stage of development in the HU-treated and control group was evaluated.  
 
Experiment 3 
 
Intermittent Culture in vitro, of Embryos in Bioavailable HU 
 
Experiment 3 was essentially a repetition of experiment 2 except that 2-cell embryos in the 
treatment group were cultured in CM containing HU (18.0 g HU/mL) for an hour followed by two 
washes in CM prior to in vitro culture in the absence of HU. This experiment was designed to simulate 
the in vivo exposure of embryos to bioavailable HU. Embryos in the control group were exposed to 
saline as described for embryos in the HU treatment group prior to being cultured in CM. This process 
was repeated everyday for the 5 days of in vitro culture. At the end of culture period, the percentage of 
embryos at blastocyst stage of development in the intermittent HU-treated and control group   
was evaluated.  
 
Statistical Analyses  
 
Data on ovarian weight, ovulation rate and serum concentrations of E2 were compared by unpaired 
“t” test while those on fertilization rate and embryo development were analyzed by Chi-Square.  Int. J. Environ. Res. Public Health 2010, 7          
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3. Results  
 
Mice in the HU treatment group sustained approximately 50% reduction (P < 0.05) in ovarian 
weight compared with their counterparts in the control group (Figure 2). Interestingly, the reduction in 
mean ovarian weight among HU treated mice was accompanied by concomitant reductions in serum E2 
concentrations (P < 0.05; Figure 3) and ovulation rate (P < 0.05; Figure 4).  
Figure 2. Mean Ovarian Weight of HU-treated Versus Control Mice. 
 
Figure 3. Effect of HU on Serum E2 Concentrations in Female Mice Treated IP with 30 
mg HU/kg for 28 days; n = 5 per Group. Results are expressed as mean ± SE (HU = treated 
mice; Control = vehicle treated mice. Asterisks indicate a significant difference from 
controls (P < 0.05). 
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Figure 4. Effect of HU on Ovulation Rate in Female Mice Treated IP with 30 mg HU/kg 
for 28 days; n = 5 per Group. Results are expressed as mean ± SE (HU = treated mice; 
Control = vehicle treated mice. Asterisks indicate a significant difference from   
controls (P < 0.05). 
 
 
Fertilization rate of oocytes recovered from HU-treated mice was 93%, comparable with that of 
recovered oocytes from control mice (95%). The ability of apparently normal 2-cell embryos 
recovered from HU-treated mice to progress to 4-cell stage of development in 36h of in vitro culture 
was comparable with their counterparts recovered from control mice. However, in vitro culture of in 
vivo generated 2-cell embryos (60 embryos/group) revealed that fewer (P < 0.05) in vivo HU-exposed 
embryos developed to blastocyst stage (19 [32%]); Figure 5 compared with 36 (60%) of their control 
counterparts that progressed to blastocyst stage of development in vitro (Figure 6). Of the remaining 
embryos, more embryos were arrested at the 8-cell stage of development among in vivo HU-exposed 
(73%; P < 0.05) compared with controls (29%) during the 5 day in vitro culture. 
Figure 5. Effect of in vivo Exposure of Embryos to HU on Their Ability to Develop to 
Blastocyst Stage; n = 60 per Group. Results are expressed in percentages (HU = treated 
mice; Control = vehicle treated mice. Asterisks indicate a significant difference from   
controls (P < 0.05). 
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Figure 6. Photomicrograph of a blastocyst with an outer cell mass (OCM), inner cell mass 
(ICM) encompassed by an intact zona pellucida (ZP; Magnification = 400X). 
 
 
On the contrary, fewer (P < 0.05) in vivo HU-exposed embryos were arrested at the morulla stage 
(27%) compared to their control counterparts (71%) during in vitro culture. The continuous culture of 
embryos in bioavailable concentration of HU in vitro resulted in approximately 88% reduction in the 
number of embryos that attained the blastocyst stage of development compared with controls   
(Figure 7). However, the intermittent exposure of embryos to bioavailable concentration of HU offered 
a modest improvement in the percentage of embryos that attained the blastocyst stage of development 
(Figure 8). This regimen of embryo culture resulted in a 75% reduction in the number of embryos that 
attained blastocyst stage compared with their control counterparts. 
Figure 7. Effect of Continuous in vitro Exposure of Embryos to Bioavailable HU   
(18 µg/mL) on Their Ability to Develop to Blastocyst Stage; n = 50 per Group. Results are 
expressed in percentages (HU = treated embryos; Control = vehicle treated embryos. 
Asterisks indicate a significant difference from controls (P < 0.05). 
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Figure 8. Effect of Intermittent in vitro Exposure of Embryos to Bioavailable HU   
(18 µg/mL) on Their Ability to Develop to Blastocyst Stage; n = 60 per Group. Results are 
expressed in percentages (HU = treated embryos; Control = vehicle treated embryos. 
Asterisks indicate a significant difference from controls (P < 0.05). 
 
 
4. Discussion  
 
In Experiment 1, we wanted to determine if HU treatment of adult female mice compromised the 
ability of the in vivo exposed ovary to function maximally. In this experiment, we observed that 
ovarian weight, the key predictor of normal folliculogenesis (E2 production) and ovulation rate were 
significantly reduced in HU-treated adult mice compared with their control counterparts, indicating 
hypogonadism among HU-treated mice. We have shown that HU is an endocrine disruptive   
chemical [12] and could have very specific effects on the different tissues within the ovary. Because of 
the intense interdependency of the different tissues within the ovary, perturbation of the function of 
one or all the tissues in the ovary by HU can compromise normal folliculogenesis, ovulatory process, 
fertilization of ovulated ova and subsequent embryo development.  
During each ovarian cycle, follicular development beyond the early antral stages is absolutely 
dependent upon FSH [16] for both proliferation and differentiation of granulosa cells and the synthesis 
of E2 via aromatization of androgen from the thecal tissue [17]. The resulting secondary follicles are 
them recruited for possible selection as dominant follicles that are triggered to ovulate under the 
stimulatory influence of E2-regulated LH surge. It is likely that the reduction in ovulation rate observed 
in this study among HU-treated versus control mice resulted from the inhibition of granulosa cell 
ribonucleotide reductase, resulting in the depletion of deoxyribonucleotide pools and subsequently 
arresting granulosa cell proliferation at late G1/early S-phase [18]. Furthermore, HU-induced reduction 
in DNA synthesis [1] can induce granulosa cell death among HU-treated versus controls. Such actions 
of HU on granulosa cells can negatively impact FSH-induced proliferation and differentiation of these 
cells and consequently lead to reduced numbers of follicles recruited for possible selection as dominant 
follicles; hence the reduced ovulation rate among HU-treated compared with control mice.  
Numerous studies have measured steroid hormones in follicular fluid as a method for distinguishing 
between healthy and atretic follicles [19-22]. The inference drawn from these studies is that healthy Int. J. Environ. Res. Public Health 2010, 7          
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follicles produce higher concentrations of E2 than either progesterone or androgen, while the reverse is 
true for atretic follicles [19,20,22].  It is conceivable that the significant reduction in serum E2 
concentrations at 48 hours post PMSG (proestrus) in HU-treated mice is a reflection of fewer healthy 
follicles progressing towards ovulation compared with their control counterparts. Hence, the reduced 
ovarian weight observed among HU-treated versus control mice is secondary to fewer corpora lutea, 
the most prominent tissues in the ovary immediately following ovulation, due to fewer numbers of 
healthy follicles that ovulated. In this study, fertilization rates of ova recovered from HU-treated and 
control mice were comparable, suggesting that in vivo exposure of oocytes to HU did not interfere with 
the fertilization process.  
Based on data raised in HeLa cells, HU exhibits antiproliferative effect in a dose-dependent   
manner [23] on proliferating cells and less so on non-proliferating cells. These are expected 
observations, because HU mainly affects DNA synthesis, thereby interfering with the growth of 
proliferating cells. Yeo et al. [24] found that HU inhibits the growth of human diploid fibroblasts by 
inducing increasing p53 and p21 levels in human diploid fibroblast cells.  
In this study, mice were treated with 30 mg HU/kg once every 24 hours for 28 days. With a half-life 
of 2–4 hours, it is possible that the daily bioavailable levels of HU reaching the granulosa cells of 
maturing follicles were not significant enough to totally inhibit proliferation. Consequently, enough 
granulosa cells were spared to prepare oocytes to respond to hCG for the attainment of the final 
meiotic maturation stage (MII) and ovulate ova equipped to facilitate normal fertilization. The 
percentage of embryos generated towards the tail end of HU treatment that attained morulla or 
blastocyst stage of development was significantly reduced during in vitro culture in the absence of HU 
compared with their control counterparts. The ability of some in vivo HU-exposed embryos to develop 
to blastocyst stage indicates resilience to this therapeutic agent by exposed embryos. Embryos being 
diploid cells are vulnerable to the antiprolifarative action of HU [24]. If this premise is true, none of 
the embryos expose in vivo to HU would develop to blastocyst stage. Perhaps the duration of exposure 
of in vivo generated embryos to this therapeutic agent was too short to completely arrest development. 
Furthermore, the removal of the embryos from in vivo exposure and placement in an in vitro culture 
medium without further exposure to HU may have reversed any arrest imposed by HU. According to 
Linke et al. [18] HU-induced depletion of deoxyribonucleotide pools and the consequent cell cycle 
arrest at late G1/early S-phase is reversible. The other scenario is that the short duration of in vivo 
exposure of 2-cell embryos to HU may have resulted in uneven arrest of the blastomeres. Because 
blastomeres at the early cleavage stage are totepotent, one viable blastomere can rescue the entire 
embryo that can develop to blastocyst stage in the absence of HU during in vitro culture.  
Experiment 2 and 3 were designed to determine if exposure of 2-cell embryos, not previously 
exposed to in vivo HU, but to continuous or intermittent HU in vitro affected development. The 
continuous  in vitro culture of embryos in the presence of HU caused a significant percentage of 
embryo death due to irreversible arrest of blastomere proliferation and subsequent apoptotic 
degeneration [18,23]. Intermittent cultures of embryos in the presence of HU slightly reduced the 
percentage of dead embryos compared with those cultured continuously. This is likely due to arrests 
imposed on the embryos in culture by HU and arrest reversal post wash followed by a 23 hour culture 
before re-exposure. This regimen of in vitro embryo culture led to only a few more embryos Int. J. Environ. Res. Public Health 2010, 7          
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progressing to blastocyst stage of development compared with their counterparts in the continuous 
regimen of embryo culture in the presence of HU.  
Although HU is a potential antineoplatic agent, inhibitor of viral development, a beneficial drug for 
the alleviation of clinical manifestations of SCD and a well tolerated drug, it is highly toxic to 
preimplantation embryos. The ability of some embryos exposed to HU to develop to blastocyst stage 
indicates resilience to xenobiotics by some embryos. However, subtle damage may still occur in the 
surviving embryos and may be expressed post partum if exposure is high enough and continuous. 
Patients on HU that are considering a family should consult with their physicians before they   
attempt pregnancy. 
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